Neil Warma has been a successful healthcare entrepreneur for over 25 years having managed and advised numerous biotechnology and pharmaceutical companies across the globe. He is the president, CEO, and board director of Mongoose Bio, a company recently spun out of the MD Anderson Cancer Center, and he focuses on transforming the treatment of both rare and common cancers with its unique cellular therapy technology. Additionally, Neil is the CEO and Board Director of ProMIS Neurosciences (Nasdaq:PMN), a publicly traded, clinical-stage company developing novel treatments for multiple neurodegenerative diseases including Alzheimer’s Disease, ALS, and Parkinson’s, based on revolutionary technology targeting misfolded proteins. Neil currently serves on the Board of Directors of the Biotechnology Innovation Organization (BIO), GenrAb Inc. and Ridgeline Therapeutics. Mr. Warma obtained an honors Bachelor of Science degree specializing in neuroscience from the University of Toronto and an International MBA from the Schulich School of Business at York University in Toronto.
General Inquiries
Forbes Middle East is a licensee of Forbes Media and extends the Forbes brand of journalism across the Arab world. Forbes Middle East’s distinctive editorial style attracts a readership of Arab leaders, entrepreneurs, C-level executives, government officials and investors united by a belief in the spirit of free enterprise and entrepreneurial values.Across the region, Forbes Middle East sets the pace for preemptive business journalism. By uncovering trends and anticipating opportunities in the regional marketplace, each monthly issue brings top executives the information critical to their success – in both Arabic and English language editions. The magazine researches and publishes original rankings, based on methodologies set by Forbes Media.